|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
PL341356A1
(en)
*
|
1997-12-22 |
2001-04-09 |
Bayer Ag |
Raf kinase inhibition employing aryl- and heteroaryl-substituted heterocyclic ureas
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
AU2003204708B2
(en)
*
|
1997-12-22 |
2006-05-25 |
Bayer Healthcare Llc |
Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
|
|
NZ505844A
(en)
*
|
1997-12-22 |
2003-10-31 |
Bayer Ag |
Inhibition of raf kinase using substituted heterocyclic ureas
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
SI1140840T1
(sl)
*
|
1999-01-13 |
2006-06-30 |
Bayer Pharmaceuticals Corp |
Omega-karboksiarilno substituirane difenil secnine kot inhibitorji raf kinaze
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
SK287419B6
(sk)
*
|
1999-01-13 |
2010-09-07 |
Bayer Corporation |
Použitie difenylových močovín substituovaných omega-karboxyarylovou skupinou ako inhibítorov rafkinázy
|
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
WO2000050425A1
(en)
|
1999-02-22 |
2000-08-31 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Polycyclo heterocyclic derivatives as antiinflammatory agents
|
|
CA2360740A1
(en)
|
1999-03-02 |
2000-09-08 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as reversible inhibitors of cathepsin s
|
|
ATE309237T1
(de)
|
1999-03-12 |
2005-11-15 |
Boehringer Ingelheim Pharma |
Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
|
|
IL144897A0
(en)
|
1999-03-12 |
2002-06-30 |
Boehringer Ingelheim Pharma |
Compounds useful as anti-inflammatory agents
|
|
HN2000000051A
(es)
*
|
1999-05-19 |
2001-02-02 |
Pfizer Prod Inc |
Derivados heterociclicos utiles como agentes anticancerosos
|
|
US6573409B1
(en)
|
1999-07-02 |
2003-06-03 |
The Nutrasweet Company |
Process for the preparation of 3,3-dimethylbutanal
|
|
ATE312823T1
(de)
|
1999-07-09 |
2005-12-15 |
Boehringer Ingelheim Pharma |
Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
|
|
US6420364B1
(en)
|
1999-09-13 |
2002-07-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compound useful as reversible inhibitors of cysteine proteases
|
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
|
US6414013B1
(en)
|
2000-06-19 |
2002-07-02 |
Pharmacia & Upjohn S.P.A. |
Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
|
|
DE10050492A1
(de)
*
|
2000-10-11 |
2002-04-25 |
Morphochem Ag |
Verfahren zur Herstellung von 5-Oxo-2,5-dihydro-furan-2-carbonsäureamiden und 6-Oxo-3,6-dihydro-2H-pyran-2-carbonsäureamiden
|
|
EP1341771A2
(en)
|
2000-11-29 |
2003-09-10 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
JP2004530690A
(ja)
|
2001-05-16 |
2004-10-07 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症性薬剤として有用なジアリールウレア誘導体
|
|
JP2004531571A
(ja)
|
2001-05-25 |
2004-10-14 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
|
|
PL395097A1
(pl)
*
|
2001-06-11 |
2011-10-10 |
Vertex Pharmaceuticals (Canada) Incorporated |
Sposób wytwarzania związku o wzorze A stanowiącego pochodną tiofenu
|
|
EP1709965A3
(en)
*
|
2001-07-11 |
2006-12-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediate diseases
|
|
ES2400070T3
(es)
*
|
2001-12-03 |
2013-04-05 |
Bayer Healthcare Llc |
Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
|
|
MXPA04007832A
(es)
|
2002-02-11 |
2005-09-08 |
Bayer Pharmaceuticals Corp |
Aril-ureas con actividad inhibitoria de angiogenesis.
|
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
WO2003072569A1
(en)
|
2002-02-25 |
2003-09-04 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
|
DE60310730T2
(de)
|
2002-07-09 |
2007-05-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
|
|
EP1615878B1
(en)
|
2003-01-14 |
2012-04-04 |
Cytokinetics, Inc. |
Compounds, compositions and methods of treatment for heart failure
|
|
CA2526285A1
(en)
|
2003-05-15 |
2004-12-23 |
Arqule, Inc. |
Inhibitors of p38 and methods of using the same
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
HRP20060073B1
(hr)
|
2003-07-23 |
2014-03-14 |
Bayer Healthcare Llc |
Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
|
|
BRPI0413585A
(pt)
*
|
2003-08-15 |
2006-10-17 |
Astrazeneca Ab |
composto ou sal farmaceuticamente aceitável ou um precursor hidrolisável in vivo deste, uso de um composto ou um sal deste farmaceuticamente aceitável, métodos para o tratamento de cáncer, e de infecções associadas com cáncer, composição farmacêutica, e, processo para preparação e uso de um composto ou um sal farmacêuticamente aceitável ou um precursor hidrolisável in vivo
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
CN101010315A
(zh)
|
2004-04-30 |
2007-08-01 |
拜耳制药公司 |
用于治疗癌症的取代的吡唑基脲衍生物
|
|
WO2006009726A2
(en)
|
2004-06-17 |
2006-01-26 |
Cytokinetics, Inc. |
Substituted urea derivatives for treating cardiac diseases
|
|
US7829560B2
(en)
|
2004-07-08 |
2010-11-09 |
Arqule, Inc. |
1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
US8178672B2
(en)
|
2004-10-19 |
2012-05-15 |
Arqule, Inc. |
Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase
|
|
JP2008523071A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ， インコーポレイテッド |
Ｍａｐキナーゼの尿素インヒビター
|
|
JP2008523072A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ， インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
|
GB0428082D0
(en)
|
2004-12-22 |
2005-01-26 |
Welcome Trust The Ltd |
Therapeutic compounds
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
CN104688697A
(zh)
|
2005-03-07 |
2015-06-10 |
拜尔健康护理有限责任公司 |
用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
|
|
EP2546246A3
(en)
|
2005-05-13 |
2013-04-24 |
Virochem Pharma Inc. |
Compounds and methods for the treatment or prevention of flavivirus infections
|
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
JP5072595B2
(ja)
|
2005-08-05 |
2012-11-14 |
中外製薬株式会社 |
マルチキナーゼ阻害剤
|
|
US7825120B2
(en)
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
|
TW200808321A
(en)
|
2005-12-15 |
2008-02-16 |
Cytokinetics Inc |
Certain chemical entities, compositions and methods
|
|
WO2007078815A2
(en)
|
2005-12-16 |
2007-07-12 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP1962852B1
(en)
|
2005-12-19 |
2017-01-25 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
CN102627657B
(zh)
*
|
2012-03-09 |
2015-01-07 |
苏州施亚生物科技有限公司 |
3-(4-甲氧基-苄基)-1h-嘧啶-2,4-二酮衍生物的合成方法
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
EP3046557A1
(en)
|
2013-09-20 |
2016-07-27 |
Stichting Het Nederlands Kanker Instituut |
Rock in combination with mapk-pathway
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
CN106470974B
(zh)
|
2014-04-17 |
2019-07-16 |
韩国巴斯德研究所 |
用于治疗病毒感染的化合物
|
|
WO2015178770A1
(en)
|
2014-05-19 |
2015-11-26 |
Stichting Het Nederlands Kanker Instituut |
Compositions for cancer treatment
|
|
HUE053286T2
(hu)
*
|
2016-10-26 |
2021-06-28 |
Ishihara Sangyo Kaisha |
Eljárás 3-metil-2-tiofénkarbonsav elõállítására
|